| 46.15 -1.28 (-2.7%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 58.18 | 1-year : | 67.96 |
| Resists | First : | 49.81 | Second : | 58.18 |
| Pivot price | 46.21  |
|||
| Supports | First : | 45.03 | Second : | 42.06 |
| MAs | MA(5) : | 45.12 |
MA(20) : | 46.39 |
| MA(100) : | 40.86 |
MA(250) : | 36.46 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 58.1 |
D(3) : | 42.7 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 49.81 | Low : | 22.7 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SRRK ] has closed above bottom band by 48.8%. Bollinger Bands are 38.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 48.14 - 48.42 | 48.42 - 48.67 |
| Low: | 44.62 - 44.91 | 44.91 - 45.17 |
| Close: | 45.73 - 46.2 | 46.2 - 46.62 |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Thu, 05 Mar 2026
A Look At Scholar Rock Holding (SRRK) Valuation After Wider Losses And New Shelf Registration - simplywall.st
Thu, 05 Mar 2026
Piper Sandler Maintains Overweight on Scholar Rock (SRRK) March 2026 - Meyka
Wed, 04 Mar 2026
Scholar Rock Holding (SRRK) Sees Price Target Raised by Truist S - GuruFocus
Wed, 04 Mar 2026
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 2025 Earnings Call Transcript - Insider Monkey
Tue, 03 Mar 2026
Scholar Rock (NASDAQ: SRRK) posts 2025 loss, expands debt capacity - Stock Titan
Tue, 03 Mar 2026
Barclays raises Scholar Rock stock price target to $53 on debt deal - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 102 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 124.7 (%) |
| Shares Short | 15,530 (K) |
| Shares Short P.Month | 14,740 (K) |
| EPS | -3.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76.7 % |
| Return on Equity (ttm) | -218.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.08 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -274 (M) |
| Levered Free Cash Flow | -147 (M) |
| PE Ratio | -14.66 |
| PEG Ratio | 0 |
| Price to Book value | 18.68 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|